Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Klein

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Research Square|August 6, 2025
Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma ClassificationYing Xu, Daniel Western, Gyujin Heo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Medrxiv : the Preprint Server for Health Sciences|July 17, 2025
Associations of <sup>18</sup> F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD ContinuumMahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2026
Associations of <sup>18</sup>F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuumMahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, et al.
Brain : a Journal of Neurology|February 13, 2019
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkersBrian A Gordon, Tyler M Blazey, Jon Christensen, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2019
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesYi Su, Shaney Flores, Guoqiao Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 23, 2024
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation modelAntoine Leuzy, Lars Lau Raket, Victor L Villemagne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Research Square|August 6, 2025
Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma ClassificationYing Xu, Daniel Western, Gyujin Heo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Medrxiv : the Preprint Server for Health Sciences|July 17, 2025
Associations of <sup>18</sup> F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD ContinuumMahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2026
Associations of <sup>18</sup>F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuumMahnaz Shekari, Armand González Escalante, Marta Milà-Alomà, et al.
Brain : a Journal of Neurology|February 13, 2019
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkersBrian A Gordon, Tyler M Blazey, Jon Christensen, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2019
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesYi Su, Shaney Flores, Guoqiao Wang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 23, 2024
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation modelAntoine Leuzy, Lars Lau Raket, Victor L Villemagne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Pageof 7